Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Buy Rating Affirmed for BridgeBio Pharma on Acoramidis’ Positive ATTR-CM Trial Outcomes

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Elevance Health (ELV)

Analysts’ Top Healthcare Picks: Avidity Biosciences (RNA), Irhythm Technologies (IRTC)